Voyager Highlights SOD1 and TAU Programs at R&D Day

On April 29, 2016, clincal-stage startup company Voyager Therapeutics conducted an R&D day for investors and media, which includes presentations on its AAV gene therapy programs for neurodegenerative diseases, including Parkinson’s disease and SOD1-ALS. The company also announced two new programs: Tau-targeting therapies for FTD and Alzheimer’s disease, and Nav1-targeting therapies for chronic pain. On the SOD1-ALS front, the company is currently optimizing and testing SOD1-silencing microRNA sequences, as well as the AAV capsids for viral delivery, and is planning to submit the IND application for VY-SOD101 for SOD1-ALS in late 2017.

The view the full webcast, click here (available until May 29).

disease-ad disease-als disease-ftd gene therapy SOD1 tau topic-clinical topic-newmethods topic-preclinical topic-randd
Share this: